Why the current system is broken and what local governments, nonprofits, and philanthropists could do to change it.

Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -- Reported highly ...

Third quarter revenues up 6% driven by EXPAREL volume growth of 9% ---- Several key milestones advance 5x30 path to growth ...

Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...

UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM ESTCompany ParticipantsAngela Wirick - Chief Financial ...

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections. It announced today ...

Doctors have always told patients with atrial fibrillation (AF) to limit caffeine, saying it could trigger irregular heartbeats, however, a new international trial shows that moderate coffee intake is ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update 100 Patients Enrolled in Phase 2b Trial of Halneuron®; Interim ...

Modern semiconductor chip design faces growing complexity due to numerous timing scenarios driven by varying operating ...

Stacking dies introduces layers of complexity driven by multi-physics interactions, which must be addressed at the start of ...

Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the ...